Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program
- 1 November 2014
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 61 (5) , 976-983
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialThe Lancet, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionNew England Journal of Medicine, 2009
- Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective studyHepatology, 2007
- Interferon therapy prolonged life expectancy among chronic hepatitis C patientsGastroenterology, 2002